Attendee Bios

Collaboration • Innovation • Inspiration

SAS | Cary, NCNovember 2–3 , 2017

2

Dawn Aubel, EdD, MPH, APNc Medical Science Liaison Hematology, Novartis Oncology Co-Chair, CEO Cancer Gold Standard Task Force

Dr. Dawn Aubel is a medical science liaison in hematology oncology at Novartis. In her previous role, she was responsible for strategy, design, implementation and evaluation of health and wellness initiatives for the large employee population of Novartis AG.

Dr. Aubel received a doctorate in health services organization and leadership from Teachers College, Columbia University. She also has a master’s degree in nursing and a master’s degree in public health from Columbia University. Her undergraduate degree in nursing is from Virginia Commonwealth University. She is certified by the American Nurses Certification Center as a Family Nurse Practitioner. Dr. Aubel has extensive experience in primary and survivorship care,

and in health services delivery. She won the CancerCare of N.J. President’s Award for her work in wellness, and the company’s Global HR Award for the cancer survivorship initiative.

Robert A. BradwayChairman, CEO Roundtable on Cancer Chairman and Chief Executive Officer, Amgen

Mr. Robert Bradway became Chairman of Amgen in January 2013 and Chief Executive Officer in May 2012. He served as the company’s President and Chief Operating Officer from 2010 to 2012, and was appointed to the Amgen board of directors in October 2011. He joined the company in 2006 as Vice President of Operations Strategy, and served as Executive Vice President and Chief Financial Officer from April 2007 to May 2010.

Prior to joining Amgen, he was a managing director at Morgan Stanley in London, where he had responsibility for the firm’s banking department and corporate finance activities in Europe. Mr. Bradway joined Morgan Stanley in New York as a health care industry investment banker in

1985 and moved to London in 1990.

Mr. Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University. He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Mr. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the university’s Leonard D. Schaeffer Center for Health Policy and Economics.

2 3

Riccardo BragliaVice Chairman and Chief Executive Officer Helsinn Healthcare SA

Mr. Riccardo Braglia is Helsinn Group’s Vice Chairman, CEO and Managing Director. He is also a member of Helsinn Holding’s board of directors, Switzerland, and of the executive committee for Helsinn Group’s strategic management. He is a board member of Helsinn Healthcare, Switzerland, as well as of Helsinn Advanced Synthesis, Switzerland. Mr. Braglia is a member of Helsinn Birex Pharmaceuticals’ board of directors, Ireland, and Chairman of Helsinn Therapeutics’ board of directors, US. He is also PDG (Président Directeur Général) – Gérant Associé of Helsinn International Services à Montecarlo.

Mr. Braglia is a board member of Thorne Research, US, and Health Elements, as well as a member of the management committee of the American Chamber of Commerce.

Mr. Braglia won the 2011 Best Entrepreneur of the Year in Italian-speaking Switzerland Award, conferred by Swiss Venture Club, as well as the 2012 Ernst & Young Award for the best Swiss Entrepreneur of the Year in the High Tech/Life Sciences category. He represented Switzerland at the Ernst & Young World Entrepreneur of the Year 2013 Award.

Mr. Braglia holds a degree in business economics with specialization in industrial management from Luigi Bocconi University, Milan.

4

George D. Demetri, MDQuick Family Chair in Medical Oncology, Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School Associate Director for Clinical Sciences, Dana-Farber/Harvard Cancer Center Director, Ludwig Center at Harvard

Dr. George Demetri has dedicated his career to translational and clinical research aimed at developing practical therapies from scientific mechanisms to treat life-threatening sarcomas and other cancers.

Dr. Demetri was a pioneer in the development of imatinib (Gleevec) in gastrointestinal stromal tumors (GIST), a molecularly-defined subset of sarcomas, as one of the first examples of targeted cancer therapy for a treatment-resistant solid tumor. Research from his collaborative efforts has resulted in FDA and worldwide regulatory approval of several other “smart drugs” for cancer, including sunitinib (Sutent) and regorafenib (Stivarga) for GIST, as well as pazopanib (Votrient),

trabectedin (Yondelis) and eribulin (Halaven) for other sarcomas. Dr. Demetri served on the Scientific Advisory Board for Plexxikon and helped develop the BRAF inhibitor vemurafenib (Zelboraf) as the first mutation-targeted therapy for a molecularly-defined subset of melanomas.

At Dana-Farber and Harvard, Dr. Demetri is a Director of the Ludwig Center at Harvard (along with Dr. Joan Brugge, PhD), leading a collaboration of more than 30 investigative teams across Harvard-affiliated institutions to find new vulnerabilities of cancers. He also directs the multidisciplinary Sarcoma and GIST Center at Dana-Farber Cancer Institute, focused on developing personalized cancer therapeutics for these mesenchymal cancers.

As a member of the clinical trials working group of the National Cancer Moonshot Initiative, led by Vice President Joe Biden, Dr. Demetri has been instrumental in raising awareness of issues relating to the discovery and development of novel anticancer therapies. He is a member of the Board of Directors of the American Association for Cancer Research (AACR), and the Chair of the AACR Science Policy and Government Affairs Committee. Dr. Demetri also teaches a Freshman Seminar at Harvard College to introduce undergraduates to the social, ethical, scientific and humanistic aspects of cancer. Dr. Demetri received his undergraduate degree in biochemistry from Harvard College and medical degree from Stanford University School of Medicine. He completed his internal medicine residency and chief residency at the University of Washington Hospitals in Seattle, and a fellowship in medical oncology at the Dana-Farber Cancer Institute and Harvard Medical School.

4 5

Amadou Diarra, PhD Head, Global Policy, Advocacy and Government Affairs Bristol-Myers Squibb

Dr. Amadou Diarra leads an integrated organization at Bristol-Myers Squibb focused on external environment dynamics, working with key stakeholders including patient support organizations, health care professionals, policymakers and industry associations. He is passionate about partnering for improved health outcomes and believes that no major health care-related challenge can be addressed unilaterally by one stakeholder entity.

Dr. Diarra joined Bristol-Myers Squibb in 1991 as market research and business development manager, Africa Division. From 1999 to 2002 he led the company’s landmark philanthropic program Secure the Future, a public-private partnership focused on care and support for women

and children infected or affected by HIV/AIDS in sub-Saharan Africa. In 2002, he was appointed general manager, Indonesia, and in 2005 became general manager, Turkey. In 2008, he assumed responsibility as general manager for the Ireland and Nordic Region and was then promoted to vice president, Access Europe. In 2010, he was appointed European vice president and general manager, UK and Ireland. During this time Dr. Diarra chaired the European Works Council and sponsored the Cardiovascular and Metabolics Disease Area Committee. As a Board member of the Association of the British Pharmaceutical Industry (ABPI), he chaired the Health Technology Assessment Task Force and the Reputation Strategy Group. He also represented ABPI on the All Wales Medicine Strategy Group (AWMSG).

Prior to joining Bristol-Myers Squibb, Dr. Diarra held the role of international market research manager at Laboratoire Fournier, Dijon. He holds a doctorate from the School of Pharmacy, University of Tours, France, and an MBA from the École Supérieure de Commerce de Tours. He also completed the General Management Program delivered by the European Center for Executive Development in collaboration with INSEAD.

Dr. Diarra represents Bristol-Myers Squibb as Chair of the Pharmaceutical Research and Manufacturers of America (PhRMA) International Section Executive Committee (ISEC) and as a Council member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). He is a member of Bristol-Myers Squibb’s Global Leadership Team, Global Diversity and Inclusion Council, and Sustainability Council.

Shannon DiBariChief Operating Officer and Executive Vice President US Chamber of Commerce

Ms. Shannon DiBari supervises the day-to-day operations of the US Chamber of Commerce, one of the largest and most active associations in the world.

Ms. DiBari oversees the budget and coordinates the strategic management of the Chamber’s various and diverse programs, initiatives and divisions. She provides leadership and direct management oversight to the Chamber’s internal infrastructure departments. She engages senior leaders across the Chamber in organizational planning and development, and leads efforts to foster a work environment that drives creativity, accountability and results.

She is also responsible for the Chamber’s historic headquarters building located across Lafayette Square from the White House, and recently spearheaded a major renovation of the nearly 100-year-old building. Ms. DiBari joined the Chamber’s staff in 1979 in the Office of the General Counsel and, over the course of her career, has steadily assumed positions of increasing responsibility across the organization. Ms. DiBari has a BA in government from the College of William and Mary and an MS in leadership and management from Marymount University.

6

Joaquin DuatoBoard Member, CEO Roundtable on Cancer Executive Vice President and Worldwide Chairman, Pharmaceuticals Johnson & Johnson

Mr. Joaquin Duato is a values-driven health care business leader who has worked in three countries and two regions over his career. He is the Chairman-Elect of the Pharmaceutical Research and Manufacturers of America (PhRMA) and a Board member of Save the Children.

Mr. Duato played an instrumental role in leading the turnaround of the Johnson & Johnson pharmaceuticals business. With a focus on creating innovative solutions and processes, he inspires employees to focus on transforming the lives of patients. With 16 new products launched since 2009 and 10 potential billion dollar medicines expected to be filed before 2019, the Johnson & Johnson pharmaceuticals sector is poised to remain one of the fastest growing

pharmaceutical companies globally.

A dual citizen of Spain and the US, Mr. Duato appreciates the value of diversity of perspectives. He is a Board member of the US Spain Council, the Executive Sponsor of the African American Leadership Council, and was recognized in 2015 as one of America’s Top 10 Hispanic Business Leaders by Hispanic Career World.

Thomas J. DonohuePresident and Chief Executive Officer US Chamber of Commerce

Since assuming his position at the US Chamber of Commerce in 1997, Mr. Thomas Donohue has built the Chamber into a lobbying and political powerhouse with expanded influence across the globe.

During his tenure, the Chamber has helped secure business victories on Capitol Hill, in the regulatory agencies, politics, courts of law and the court of public opinion, and before governments around the world.

In an era of economic and fiscal challenges, Mr. Donohue has led efforts to expand trade and domestic energy production, rebuild America’s infrastructure, combat new regulations, protect

intellectual property, revitalize capital markets, and advocate legal, tax, education and entitlement reform. In addition, he has challenged attacks on free enterprise, while working to protect the business community’s right to speak and participate in the political and policy affairs of the nation.

Mr. Donohue established the US Chamber Institute for Legal Reform, which advances significant legal reforms in the courts, at the state and federal levels, and in elections for state attorneys general and Supreme Court judges. He has dramatically expanded the activities of the US Chamber Litigation Center, the Chamber’s law firm. And he has reinvigorated the US Chamber of Commerce Foundation, which houses Hiring Our Heroes, a program that identifies job opportunities for tens of thousands of returning veterans and military spouses.

Previously, Mr. Donohue served as President and CEO of the American Trucking Associations and Deputy Assistant Postmaster General of the US. He earned a bachelor’s degree from St. John’s University and a master’s degree from Adelphi University. He is a 2013 recipient of the Horatio Alger Award. He holds the highest civilian honor from Germany and South Korea, as well as the Order of the Crown (Commander Class) presented by the Crown Prince of Belgium.

6 7

Dana DornsifeChairman of the Board and Founder Lazarex Cancer Foundation

Mrs. Dana Dornsife began the nationwide public non-profit organization Lazarex Cancer Foundation in 2006 with the mission to improve the outcome of cancer care by giving hope, dignity and life to advanced stage cancer patients and the medically underserved. The organization achieves this mission by providing assistance with ancillary costs for FDA clinical trial participation beyond those covered by the drug sponsor, identifying clinical trial options, and through community outreach and engagement. Mrs. Dornsife recently expanded the mission at Lazarex to bring transformational change to the bench to bedside process of clinical trial enrollment, retention, minority participation and equitable access with IMPACT (IMproving Patient Access to Cancer Clinical Trials). She is a graduate of Drexel University in Philadelphia and

launched several businesses prior to migrating to the non-profit sector.

Mrs. Dornsife is a board member of the USC Center for Civic Engagement and the USC Brain and Creativity Institute within the USC Dornsife College of Letters, Arts and Sciences. She is Vice Chair of the governing board of the Yosemite Conservancy, in addition to being a council member. She is a member of the Mass General President’s Council. Mrs. Dornsife and her husband, Dave Dornsife, a USC Trustee, support the largest privately funded WASH initiative (Water, Sanitation and Hygiene) in 24 African countries through World Vision, an international humanitarian agency.

Shahram Ebadollahi, PhD, MBAVice President, Innovations and Chief Science Officer IBM Watson Health

Jim GoodnightChief Executive Officer SAS

As the CEO of SAS, the world’s leading business analytics software vendor, Dr. Jim Goodnight has led the company since its inception in 1976, overseeing an unbroken chain of revenue growth and profitability unprecedented in the industry. He is recognized globally for being a trailblazer among companies that top great workplace rankings, including being No. 1 on several country and multinational lists. Harvard Business School named Dr. Goodnight a Great American Business Leader, and he was named one of America’s 25 Most Fascinating Entrepreneurs by Inc. magazine. A champion of education reform, Dr. Goodnight sees education as critical to the success of individuals, organizations and nations.

8

Mimi Hancock, PhDHonorary Member, CEO Roundtable on Cancer Retired Partner, Spencer Stuart

Dr. Mimi Hancock served as a member of Spencer Stuart’s Life Sciences Practice through 2016, working out of the San Francisco office. Her executive search experience included assignments for organizations ranging from emerging life sciences companies to multinational biotechnology, pharmaceutical and medical technology firms. She has executed searches for board members as well as senior executives in general management, R&D, a variety of commercial, finance and business development positions.

Before entering the executive search industry, Dr. Hancock served as Vice President of Operations and co-founder at Avigen, a startup gene therapy company. For two years prior, she

was the Director of Cell Biology at Somatix Therapy Corporation, a publicly held company focused on gene therapy. Earlier in her career, Dr. Hancock worked at Triton Biosciences, where she conducted pioneering research on a novel therapeutic approach targeting the Her2 protein in breast and ovarian cancer (Hancock et al.; Cancer Research, 1991). She began her career in health care with Peralta Cancer Research Institute as a staff scientist, and previously served on the board of directors of Bionovo, a public company developing novel therapeutics for breast cancer and women’s health.

Dr. Hancock is currently devoting time to serving in various advisory and mentoring roles for board-ready executives, as well as career development for students in STEM programs.

E. Wayne Holden, PhDPresident and Chief Executive Officer RTI International

Dr. E. Wayne Holden, PhD, is RTI International’s fourth President and Chief Executive Officer. He joined RTI as Executive Vice President of Social and Statistical Sciences in 2005, overseeing the organization’s largest unit. Prior to joining RTI, he served as Vice President, Senior Vice President, and, ultimately, President of the research company ORC Macro. Before joining ORC Macro in 1998, he had a successful career in academia, serving more than 10 years in a variety of roles in the Department of Pediatrics at the University of Maryland’s School of Medicine. Dr. Holden holds appointments as an adjunct professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine and as an adjunct professor in the Department of Health Policy and Management at the University of North Carolina at Chapel Hill Gillings

School of Global Public Health. Dr. Holden is a fellow of the American Psychological Association and has authored more than 140 articles, books and book chapters on various topics in clinical child/pediatric psychology and health services research. He currently serves on the Board of Directors for the Research Triangle Foundation and the Emily Krzyzewski Center. He is also on the Board of Advisors for the Frank Hawkins Kenan Institute of Private Enterprise and is a member of the Children’s Mental Health Network Advisory Council.

8 9

Patrick HomerGlobal Life Sciences Commercial Practice Principal SAS

Patrick Homer leads the global commercial life sciences practice at SAS and has been driving the evolution of SAS’ advanced analytical solutions in this sector. In addition, he is also responsible for global market development of clinical and real-world data sharing activities across life sciences and academic institutions. Joining SAS in 2008, Homer brought 20 years of business experience from the commercial life sciences sector.

Prior to SAS, Homer served as Business Development Director at Innovex Limited (now Quintiles Commercial), developing strategic outsourced salesforce solutions and salesforce effectiveness initiatives to major pharmaceutical and health care organizations.

Homer earned his MBA with a major in strategy and marketing from University College of Cardiff Business School and a bachelor’s degree in microbiology from University College of Swansea.

Axel Hoos, MD, PhDSenior Vice President Therapeutic Area Head, Oncology R&D GlaxoSmithKline

As leader of the Oncology TA, Dr. Axel Hoos oversees both its discovery and development functions, and builds GSK’s oncology portfolio across several modalities, including antibodies, small molecules, bispecific molecules, and cell and gene therapies. The TA’s scientific focus is on immuno-oncology, epigenetics and cell therapy. Dr. Hoos also serves on the Scientific Advisory Board of the HIV Cure Center, a co-venture of GSK and the University of North Carolina at Chapel Hill.

Dr. Hoos is Executive Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), Non-executive Director on the Board of Imugene, Co-Chairman of the Cancer Immunotherapy

Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). He also serves as a Scientific Advisory Group member at the Parker Institute for Cancer Immunotherapy (PICI), and Industry Co-Chair of the Partnership for Acceleration Cancer Therapies (PACT) of the US Cancer Moonshot.

His efforts in medicines development and global health focus on novel and transformational therapies for life-threatening diseases, scientific and procedural innovation, and broad collaboration across multiple constituents to solve complex health problems. Through Dr. Hoos’ leadership a new paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of immuno-oncology.

Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS), where he developed Yervoy (Ipilimumab), the first life-extending therapy in immuno-oncology. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics).

Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ), both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich, Germany, and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.

10

Charles Hugh-Jones, MDChief Medical Officer Pfizer Oncology

Dr. Charles Hugh-Jones has 25 years of experience leading complex organizations as a physician and life science executive.

Prior to Pfizer, Dr. Hugh-Jones spent six years at Sanofi, where he first led North America Medical Oncology, and then spent four years as Chief Medical Officer for the region.

As Chief Medical Officer he had responsibility for all medical operations, including the medical units for immunology, diabetes, oncology, cardiovascular, consumer health and specialized therapeutics, as well as medical operations, drug safety, quality, pharmaco-economics, field medical and Canada.

During this time, Dr. Hugh-Jones led complex and varied initiatives. These ranged from successful FDA advisory committees and multiple drug launches, including the PCSK9 class, to challenging national drug recalls, restructurings and integrations.

In the same period, he personally led the team that conceptualized, designed and executed the not-for-profit Project Data Sphere that has become the first large-scale and fully open access clinical data sharing platform. The platform, covered in journals such as Nature, JNCI and Science, has become the data source for oncology secondary research and computational research challenges, including the IBM DREAM PCF Prostate cancer challenge.

Dr. Hugh-Jones trained in both neuroscience and medicine in London University, becoming board certified in internal medicine and then entering the radiology fellowship program at the Royal Postgraduate Medical School, Hammersmith Hospital, London.

After practicing for eight years in the UK, he joined the pharmaceutical industry, moving to the US to work with Schering AG/Bayer, Enzon and Sanofi in roles of increasing seniority in R&D, medical and commercial. He is a Fellow of the Royal College of Physicians of the UK.

10 11

Carole HuntsmanNorth America Head of Multiple Sclerosis, Oncology and Immunology Sanofi Genzyme

Ms. Carole Huntsman is responsible for driving the US launches of Dupixent and Kevzara, expanding Sanofi Genzyme’s leadership in Multiple Sclerosis, and sustaining the renewed growth of the organization’s oncology business.

Previously, Ms. Huntsman was Global Lead, Multiple Sclerosis. In this capacity, she was responsible for short- and long-term strategic planning and direction for the MS brands in markets globally. She was also responsible for global support to the countries marketing and planning to market MS brands. Prior to this position, Ms. Huntsman was the Vice President, Multiple Sclerosis Business Unit Head, North America, where she was responsible for hiring,

training and leading the US Commercial Team through the launch of Aubagio in September 2012 and Lemtrada in February 2015. As Regional BU Head, Ms. Huntsman was also responsible for the MS performance in Canada.

Before joining Sanofi Genzyme in January 2012, Ms. Huntsman was the Senior Vice President, Neurodegenerative Diseases and Rheumatology at EMD Serono, responsible for strategic direction and management of all US commercial operations for the MS Therapeutic Area, including sales, marketing and patient support services.

In her 25 years of pharmaceutical and biotech experience, Ms. Hunstman has also worked at Pfizer Inc. and Muro Pharmaceuticals, an ASTA Medica company, in commercial roles of increasing responsibility. Additionally, Ms. Huntsman was commissioned as an officer in the US Army, spending four years on active duty and more than twelve years in the Army Reserves.

Ms. Huntsman earned her MBA with a concentration in marketing and consulting from Boston College – Wallace E. Carroll Graduate School of Management and her BA in history from Boston College.

12

Robert A. IngramFounding Chairman, CEO Roundtable on Cancer General Partner, Hatteras Venture Partners

Mr. Robert Ingram, also known as Bob, is a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies. Prior to joining Hatteras, Mr. Ingram was Chief Executive Officer and Chairman of Glaxo/Wellcome. Mr. Ingram co-led the merger and integration that formed GlaxoSmithKline. Upon reaching mandatory retirement age of 60, Mr. Ingram served as the Vice Chairman, Pharmaceuticals at GSK before becoming Strategic Advisor to the CEO of GlaxoSmithKline Plc. Mr. Ingram is Chairman of the boards of BioCryst Pharmaceuticals, Novan (a late-stage pharmaceutical company focused on dermatology), and Viamet Pharmaceuticals, a private company focused on anti-infective research. He also serves as the Lead Director on the board of Cree. In 2013, Mr. Ingram received the NACD B. Kenneth West

Lifetime Achievement Award from the National Association of Corporate Directors.

At the request of President George H.W. Bush, Mr. Ingram formed and chaired the CEO Roundtable on Cancer. In 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. In 2014, he received the North Carolina Award for Public Service, the highest civilian honor the state can bestow on an individual. Mr. Ingram serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GlaxoSmithKline Foundation.

Mr. Ingram is a member of numerous other civic and professional organizations, including the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, CEO Roundtable on Cancer, and the Advisory Council of the Congressional Task Force on Biomedical Research and Innovation. He graduated from Eastern Illinois University with a BS degree in Business Administration.

Rebecca JolleySenior Vice President Strategic Marketing Commercial Head Oncology, Strategic Business Unit Bayer HealthCare

Ms. Rebecca Jolley oversees the global commercial strategy of the Bayer Oncology inline brands and late development pipeline.

Prior to joining Bayer in April 2017, Ms. Jolley was Senior Vice President for the Americas Commercial Oncology Business Group at Eisai. Previously, she was at Novartis Oncology, where she spent over two decades in a variety of increasingly responsible roles, including sales, market access, marketing, brand leadership and general management. She started her career with Novartis in the UK, and then transferred to the US to join Novartis Oncology. During her tenure, she held a number of executive leadership roles that included Vice President, Oncology General

Manager for Australia and New Zealand; Vice President, US Oncology Marketing; and Vice President, Global Disease Leader Chronic Myeloid Leukemia.

Ms. Jolley has a track record of success in launching oncology brands, developing and collaborating on disease education initiatives, implementing return-to-growth strategies, and leading large cross-functional teams to deliver high-quality value to healthcare providers and patients. She is driven by a strong sense of purpose to inspire her team toward creative and original solutions for patients with high unmet needs.

Ms. Jolley is a graduate of Lancaster University in England, where she holds a BSc Honors First Class in geography and biological sciences. She has been a member of the Healthcare Businesswomen’s Association (HBA) since 2005.

12 13

Raymond C. JordanSenior Vice President, Corporate Affairs Amgen

Mr. Raymond Jordan is responsible for strategic communications across Amgen, including internal and external communications, issues management and philanthropy. Prior to joining Amgen in 2012, Mr. Jordan served as Vice President of Public Affairs and Corporate Communication for Johnson & Johnson. He joined the company in 2003 as Vice President, Group Communications, where he was focused on strategic communications for the Medical Devices and Diagnostics Group until he was appointed chief communication officer in 2004, ultimately overseeing the public affairs and corporate communications for more than 250 operating companies in 60 countries. Prior to Johnson & Johnson, Mr. Jordan was Vice President of Communications and Information for Pfizer, where he held a range of positions over the

course of 17 years. Earlier in his career, he was a reporter for a regional daily newspaper, held positions with Bristol-Myers and Dun & Bradstreet, and was co-founder of a management consulting firm.

Throughout the years, Mr. Jordan has served the industry as chair of PhRMA’s Public Affairs section and the National Pharmaceutical Council’s User Group, and as a member of the board of directors of the Foundation for American Communications, the board of trustees of the Institute for Public Relations, and the Seminar Committee. He has also served as a board member of the Arthur W. Page Society. He is a graduate of Yale University and earned an MBA in marketing and finance from Columbia University.

Neal F. Kassell, MDChairman, Focused Ultrasound Foundation

Dr. Neal Kassell is the founder and chairman of the Focused Ultrasound Foundation. He was a Professor of Neurosurgery at the University of Virginia from 1984 until 2016, where he was co-chair of the department until 2006.

Before moving to Charlottesville, Dr. Kassell was on the faculty at the University of Iowa for seven years. He received both his undergraduate and medical education at the University of Pennsylvania. After internship and two years of neurology and neurosurgery residency in Philadelphia, Dr. Kassell completed his neurosurgical training with Dr. Charles Drake at the University of Western Ontario.

In April 2016, Dr. Kassell was appointed by Vice President Joe Biden to the National Cancer Institute’s Blue Ribbon Panel for Cancer Moonshot Initiative. Dr. Kassell has served on many standing and ad hoc committees of the National Institutes of Health and in an editorial capacity for a variety of academic journals. He has contributed more than 500 publications and book chapters to the literature. Dr. Kassell is a member of numerous medical societies in the US and abroad.

Dr. Kassell was a founder of Interax Inc., the Virginia Neurological Institute, Multimedia Medical Systems Inc., the Neuroclinical Trials Center, the NeuroVenture Fund, MedSpecialists.net, and the Focused Ultrasound Foundation. He has served on a number of public and private sector boards, including Eclypsis Corporation, INC Research, the Prostate Cancer Foundation, Virginia National Bank, InSightec Inc., The Lagesse Foundation, and Expedition Trust Company. He currently serves as a director of the Charlottesville Tuesday Evening Concert Series, and the Focused Ultrasound Foundation. He is a shareholder of Insightec Inc.

14

Sean Khozin, MD, MPHAssociate Director, Oncology Center of Excellence US Food and Drug Administration

Dr. Sean Khozin is associate director at FDA’s Oncology Center of Excellence and founding director of Information Exchange and Data Transformation (INFORMED), an incubator for collaborative oncology regulatory science research focused on supporting innovations that enhance FDA’s mission of promotion and protection of the public health. Drawing from the expertise of a diverse group of oncologists, data scientists, statisticians, and entrepreneurs-in-residence, INFORMED is expanding organizational and technical infrastructure for algorithmic analytics and examining modern approaches in evidence generation to support regulatory decisions. The research portfolio of INFORMED includes investigations into the use of real-world data for clinical evidence generation and prospective pragmatic clinical trials, testing the utility

of biosensors and the internet of things to quantify intrinsic and extrinsic variables influencing the patient’s experience, identifying opportunities for machine learning and artificial intelligence to improve existing practices, and exploring the utility of emerging technologies such as blockchain to enable secure exchange of health data at scale.

Previously, Dr. Khozin was in private practice in New York City, an attending physician at St. Vincent’s Hospital in Manhattan, and an entrepreneur specializing in building health information technology systems with virtual patient management (including video, structured email, short message service and remote biometric monitoring) and point-of-care data visualization and analytics capabilities.

Dr. Khozin is an adjunct Clinical Investigator at the National Cancer Institute and a research affiliate at the Massachusetts Institute of Technology.

Kenneth B. Lee, Jr.Chief Financial Officer, CEO Roundtable on Cancer General Partner, Hatteras Ventures

Mr. Ken Lee is involved in deal sourcing, investment decisions and implementing exit strategies as a general partner of HVP III. He is also a general partner for HVP II, where he has played an important role in deal sourcing, syndication and management recruitment, and evaluation. Mr. Lee is the former co-head of International Life Sciences for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world.

Mr. Lee got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the firm’s national life sciences practice, he advised numerous high-profile life

science companies with their initial public offerings, mergers and acquisitions, and strategic financings. These companies included Affymax, Affymetrix, Applied Immune Sciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA and Collagen.

Mr. Lee is a nationally recognized financial matters expert and serves on the boards of CV Therapeutics, Abgenix, OSI Pharmaceuticals, Pozen, Inspire Pharmaceuticals (ISPH), Maxygen (MAXY) and Clinverse. He is the Chairman of the Board of Clinipace and former Chairman of the Board of Inspire Pharmaceuticals Inc. (ISPH).

14 15

Douglas R. Lowy, MDDeputy Director National Cancer Institute (NCI)

A cancer researcher for more than 40 years, Dr. Douglas Lowy has served as Deputy Director of the NCI since 2010. He received the National Medal of Technology and Innovation from President Obama in 2014 for his research that led to the development of the human papillomavirus (HPV) vaccine. As chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at NCI, Dr. Lowy’s research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth. His laboratory, in close collaboration with John T. Schiller, PhD, was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the three US Food and Drug Administration-approved HPV vaccines.

Dr. Lowy is a member of the National Academy of Sciences (NAS), as well as the Institute of Medicine of the NAS. For their pioneering work, Dr. Lowy and Dr. Schiller have received numerous honors in addition to the National Medal, including the Federal Employee of the Year Award in 2007 from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, and the 2017 Lasker-DeBakey Clinical Medical Research Award.

Dr. Lowy received his medical degree from New York University School of Medicine, New York City, and trained in internal medicine at Stanford University, California, and dermatology at Yale University, New Haven, Connecticut.

Anne LubenowDeputy Executive Officer National Cancer Institute (NCI)

Jason E. Maddock, PhD, FAAHBDean and Professor, School of Public Health Texas A&M University

Dr. Jason Maddock assumed the leadership of the School of Public Health in February 2015. He previously served as the director of the University of Hawaii Public Health Program for eight years. He is internationally recognized for his research in social ecological approaches to increasing physical activity.

Dr. Maddock has been named the Bank of Hawaii Community Leader of the Year and received the Award of Excellence from the American Public Health Association, Council on Affiliates. He has chaired the Hawaii state board of health and was a charter member of the NIH study section on Community-Level Health Promotion. He has served as principal investigator on over

$18 million in extramural funding. He is an author of over 100 scientific articles and 150 chapters and abstracts. He is the Immediate Past President of the American Academy of Health Behavior. His research has been featured in several national media outlets, including The Today Show, Eating Well, Prevention and Good Housekeeping.

Dr. Maddock has given invited lectures in numerous countries, including Australia, Korea, Japan, China, Taiwan, Indonesia, El Salvador, Austria and Brazil, and he holds honorary professorships at two universities in China. He received his undergraduate degree in psychology and sociology from Syracuse University and his master’s and doctorate degrees in experimental psychology from the University of Rhode Island.

16

François MaisonrougeSenior Managing Director Evercore Partners

As a Senior Managing Director in Evercore Partners’ advisory business, Mr. Maisonrouge was involved in advising BTG on its acquisition of Galil; Medivation in its defense across from Sanofi; Shire on its acquisitions of Baxalta and Dyax and in its defense across from Abbvie; AstraZeneca in its defense across from Pfizer; Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories; Aptalis on its sale to Forest Pharmaceuticals; Bristol-Myers Squibb on its acquisition of Amylin and sale of half of its interest in Amylin to AstraZeneca; Fenwal on its sale to Fresenius; Sage Products on its sale to Madison Dearborn; Terumo on its acquisition of CaridianBCT; Sanofi on its acquisition of Genzyme and of Merck’s 50 percent stake in Merial; Movetis on its sale to Shire; TPG on its acquisition of IMS Health; and Wyeth on its combination with Pfizer.

Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse, where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology. At Credit Suisse, he was responsible for leading the firm’s relationships with large health care clients such as Johnson & Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche and Teva, most notably in executing mergers and acquisitions and capital raising transactions.

Mr. Maisonrouge has an MS in engineering from Ecole Centrale de Lyon and an MBA from Harvard Business School. He is a member of the board of advisers of the Harvard Business School Health Care Initiative, and the Director of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d’honneur.

Jamey MillarSenior Vice President, Managed Markets and Government Affairs GSK, US Pharmaceuticals

In his role with GSK, Mr. Jamey Millar leads all US payer functions, as well as government relations and public policy. Mr. Millar continues to serve as a member of the Corporate Leadership Team as he did in his prior role as Vice President and Head of the US Oncology business.

Mr. Millar has extensive sales and marketing experience working with providers, hospitals, health systems, and public and private payers across therapeutic areas, including respiratory, GSK’s largest therapeutic area. He has held a number of leadership positions since joining GSK in 2001, including four years in Managed Markets as Vice President, Strategic Pricing, Contracting and Payer Marketing. Prior to joining GSK, he spent 11 years with Procter & Gamble, where he held a

variety of positions, including Country Manager for the UK, Netherlands and Ireland.

16 17

Ann Murphy, PhDPublisher and Managing Editor The Oncologist, STEM CELLS and STEM CELLS Translational Medicine

Dr. Ann Murphy has managed STEM CELLS, the oldest journal in the area of stem cells and regenerative medicine, for 35 years. She maintains the journal’s excellence as it exponentially expands its size and scope as a top-tier global peer-reviewed journal devoted to stem cell biology.

STEM CELLS Translational Medicine (SCTM), now in its sixth volume, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. As executive editor, Dr. Murphy works closely with founding editor-in-chief Anthony Atala.

Dr. Murphy is also one of the Founding Managing Editors of The Oncologist journal, a monthly international peer-reviewed journal for physicians devoted to cancer patient care, and has guided and nurtured its growth and development over its 22-year history. She has also led The Oncologist Continuing Medical Education Program from its inception and is Director General of the Society for Translational Oncology (STO), accredited by the ACCME.

Dr. Murphy played a salient role when the senior editors of The Oncologist founded STO in 2000 to fill the gap between discovery of new oncology treatments and their global translation into oncology practice.

Dr. Murphy holds a PhD with distinction in literature from New York University. She serves on the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center. She is a published authority on the Irish literary renaissance and the biographer of the Irish playwright and poet Padraic Colum.

Martin J. Murphy, DMedSc, PhD, FASCOChief Executive Officer, Co-Founder, CEO Roundtable on Cancer

Dr. Martin Murphy is a member of the National Cancer Policy Forum of the National Academy of Medicine of the National Academy of Sciences and a Director of the Foundation for the National Institutes of Health. He is a Fellow of the American Society of Clinical Oncology, and founding Executive Editor of the peer-reviewed biomedical journal The Oncologist, Stem Cells and Stem Cells Translational Medicine.

A co-founder of the Society for Translational Oncology; a member of the Scientific Advisory Board of Hatteras Venture Partners; a charter member of the International Advisory Board of the VU University Medical Imaging Center; and a charter member of Queen’s University

Belfast School of Medicine International Review Board, Dr. Murphy is also Chairman Emeritus of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO); convener of ACT-China; and a steering committee member and senior consultant to the Chinese Society of Clinical Oncology.

Dr. Murphy is founding CEO of Project Data Sphere LLC, a nonprofit enterprise devoted to cancer clinical trial data transparency, data sharing and data analysis, founded by the CEO Roundtable on Cancer’s Life Sciences Consortium.

18

Arthur M. PappasChairman and Chief Executive Officer Pappas Capital

Mr. Art Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He founded Pappas Capital in 1994, and over the past two decades the firm has managed more than $535 million in capital and invested in more than 70 companies.

Mr. Pappas currently serves as a director for Aura Biosciences and OrphoMed, and as a board observer for Amplyx Pharmaceuticals, Kezar Life Sciences and Real Endpoints. Prior to founding Pappas Capital, he held senior-level leadership positions at several multinational pharmaceutical companies, including Glaxo Holdings plc, Abbott International, Merrell Dow Pharmaceuticals

and the Dow Chemical Company. He previously served as Chairman for CoLucid Pharmaceuticals (NASDAQ: CLCD) (acquired by Eli Lilly in 2017), and on the boards of Afferent Pharmaceuticals (acquired by Merck in 2016), Chimerix (NASDAQ: CMRX), Quintiles Transnational Corp. (NASDAQ: QTRN now NYSE: Q), TYRX (acquired by Medtronic in 2013), Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics (acquired by BioMarin in 2010), CardioDx, and Embrex (NASDAQ: EMBX) (acquired by Pfizer in 2006). He also served as a board observer for Plexxikon, which was sold to Daiichi Sankyo in 2011.

Mr. Pappas serves on the boards of the North Carolina Biotechnology Center, the Medical University of South Carolina Foundation for Research Development, The Wistar Institute, the Duke Cancer Institute, and the BioExec Institute. He is also a member of the CEO Roundtable on Cancer and BayHelix. Mr. Pappas is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division. He received a BS in biology from Ohio State University and an MBA in finance from Xavier University.

Philip Porter, JD, MedSpecial Counsel, CEO Roundtable on Cancer of Counsel, Hogan Lovells US LLP

Mr. Philip Porter cut his legal teeth on software license deals in the early 1980s, when most people had only a vague idea about computers, and no clue about software. A few years later, he was negotiating ownership of inventions made during clinical trials at a time when contracts did not address ownership. Before the rest of us had heard of the World Wide Web, Mr. Porter was writing website development agreements and auditing client websites for compliance with rapidly developing laws.

Mr. Porter helps clients with commercial transactions involving technology and intellectual property. He has led a team that structured a technology outsourcing transaction valued at over

$1 billion, helped an offshore university acquire one of the world’s largest supercomputers and the skills needed to operate and maintain it, and orchestrated what was believed to be the first deal between a US pharmaceutical company and a Chinese research firm to co-develop compounds.

Since 2013, Mr. Porter has focused on providing pro bono assistance to a nonprofit that makes clinical trial data available for access by researchers worldwide. As part of a US government program, he has conducted training for lawyers and academics from third-world countries in structuring and negotiating technology transfer transactions. He also conducts continuing legal education programs and development classes.

18 19

Chandra Ramanathan, PhD, MBAVice President and Head, East Coast Innovation Center Bayer HealthCare LLC

Chandra Ramanathan is Vice President and Head of East Coast Innovation Center at Bayer. He is responsible for establishing the innovation center, building an innovative product portfolio with key academic partners, driving external scientific leadership and engaging with members of the local innovation ecosystem. His previous roles at Bayer include the global lead for External Innovation – Life Sciences, the Global Launch Team leader of Copanlisib and Head of Pipeline Marketing.

Before joining Bayer, Dr. Ramanathan worked at Wyeth (Pfizer) and Bristol-Myers Squibb in various roles, including Global Brand Team Leader, licensing/business development,

neuroscience strategy, drug discovery and applied genomics.

Dr. Ramanathan has worked in pharmaceutical product development and commercialization for more than 20 years. He holds an MBA from the Columbia Business School, PhD in genomics/bioinformatics, MS in medicinal chemistry and BS in pharmacy.

David M. Reese, MDSenior Vice President, Translational Sciences, Amgen Co-Chair, Life Sciences Consortium Task Force

Dr. David Reese is responsible for medical sciences, comparative biology and safety sciences, and pharmacokinetics and drug metabolism at Amgen. Prior to assuming this role, Dr. Reese was Vice President of Translational Sciences and therapeutic area head for oncology global development. He joined Amgen in 2005 and has served in various roles in global development and medical sciences.

Prior to joining Amgen, Dr. Reese was Director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a Co-Founder, President and Chief Medical Officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization.

Dr. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in internal medicine and hematology/oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco.

20

Mace L. Rothenberg, MDCo-Chair, Life Sciences Consortium Task Force Chief Development Officer, Oncology Pfizer

Dr. Mace Rothenberg is responsible for overseeing clinical research and development activities for all promising oncology products in Pfizer’s Global Product Development Group. He is a member of the Global Product Development and Pfizer Oncology Leadership Teams and Pfizer’s Senior Leadership Council. He also co-chairs the Life Sciences Consortium of the CEO Roundtable on Cancer, is a member of the National Cancer Policy Forum of the National Academy of Medicine, and serves on the NYU School of Medicine’s Alumni Board of Governors.

Dr. Rothenberg came to Pfizer in 2008 after 25 years in academia at the University of Texas Health Science Center – San Antonio and Vanderbilt University, where he focused on early-stage drug

development, clinical trial design, and the coordinated laboratory-clinical evaluation of new therapies for gastrointestinal cancers. He chaired the pivotal clinical trials that led to FDA approval of irinotecan (CPT-11, Camptosar®) and oxaliplatin (Eloxatin®) for colorectal cancer, and a key trial used as the basis for approval of gemcitabine (Gemzar®) for pancreatic cancer. At Pfizer, Dr. Rothenberg’s organization has been responsible for the successful development and regulatory approval of seven new cancer drugs over a period of eight years: crizotinib (Xalkori®) for ALK+ and ROS1+ non-small cell lung cancer, axitinib (Inlyta®) for renal cell carcinoma, bosutinib (Bosulif®) for Ph+ chronic myelogenous leukemia, palbociclib (Ibrance®) for ER+ advanced breast cancer (Prix Galien Award winner in 2016 for Best Pharmaceutical Product), avelumab (Bavencio®) for Merkel cell and urothelial carcinomas, inotuzumab ozogamicin (Besponsa®) for acute lymphocytic leukemia, and gemtuzumab ozogamicin (Mylotarg®) for acute myelogenous leukemia.

Dr. Rothenberg is the recipient of the American Cancer Society’s Lane W. Adams Quality of Life Award and the American Society of Clinical Oncology’s Statesman Award. He is a Fellow of the American College of Physicians and the American Society of Clinical Oncology. Dr. Rothenberg received his BA from the University of Pennsylvania, his MD from the New York University School of Medicine, his post-graduate training in internal medicine at Vanderbilt University and his medical oncology training at the National Cancer Institute.

Eric H. Rubin, MDVice President and Therapeutic Area Head, Oncology Early Development Merck Research Laboratories

Dr. Eric Rubin has focused on cancer drug development for over 25 years, initially as a faculty member at the Dana-Farber Cancer Institute, then as a senior leader of the Cancer Institute of New Jersey. His research efforts focused on mechanisms of resistance to DNA topoisomerase-targeting drugs, and his laboratory cloned a novel topoisomerase I- and p53-interacting tumor suppressor gene, TOPORS. In 2008 Dr. Rubin was recruited to Merck as Vice President, Oncology Clinical Research. He led the development of the anti-PD-1 antibody pembrolizumab, which was the first anti-PD-1 therapy approved in the US, and in the identification of the significant activity of this antibody across several cancer types. In his current role he oversees oncology early development and translational research activities at Merck.

Dr. Rubin has authored over 100 original, peer-reviewed publications and book chapters related to oncology translational research, clinical trials and drug development. He has served frequently as a member of National Cancer Institute and American Cancer Society study sections, as well as on program committees for the American Association of Cancer Research and the American Society of Clinical Oncology. In addition, he serves on several editorial boards. Dr. Rubin obtained his medical degree from the University of South Florida and completed residency at Yale-New Haven Hospital.

20 21

Charles A. Sanders, MDChairman Emeritus, Foundation for the National Institute of Health (FNIH) Retired Chairman and Chief Executive Officer, Glaxo

Dr. Charles Sanders is retired from Glaxo Inc., where he served as Chief Executive Officer from 1989 through 1994 and Chairman of the Board from 1992 through 1995. Prior to joining Glaxo, Dr. Sanders spent eight years with Squibb Corporation, where he held a number of positions, including Vice Chairman. Previously, Dr. Sanders was General Director of Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. He is currently a member of the Institute of Medicine of the National Academy of Sciences, Chairman Emeritus of Project HOPE and Chairman Emeritus of the Foundation for the National Institutes of Health. He is also past Chairman of the UNC Health Care System. Additionally, he served on the boards of several publicly traded companies. He earned his MD from the University of Texas Southwestern Medical School.

Peter Sandor, MD, MBAVice President, Global Therapeutic Area Head Oncology in Marketing Strategy Astellas

Dr. Peter Sandor provides commercial leadership for projects within the oncology therapeutic area at Astellas and plays an integral role in expansion of the company’s presence in oncology.

Dr. Sandor has 20 years of progressive marketing experience. He was recently the Vice President, Global Marketing Oncology at Amgen responsible for the successful realization of the commercial potential for Amgen’s oncology assets. Prior to Amgen, he held positions at Bayer Healthcare, including Head of Strategy and Portfolio Management Specialty Medicine, Commercial Development and Life Cycle Management Global Oncology. He also worked for Berlex Laboratories as the lead of the global launch team for a key oncology compound, and

held multiple marketing roles with Schering AG in Germany and Hungary.

Dr. Sandor started his career in bench research as a scientific advisor of the Hungarian Academy. He received his MDS Marketing and MBA from Middlesex University, London, and Faculty of Business and Economy, University of Pécs, Hungary, and his MD from University of Pécs, Hungary.

22

Jay J. Schnitzer, MD, PhDVice President and Chief Technology Officer The MITRE Corporation

Dr. Jay Schnitzer is Vice President and Chief Technology Officer at The MITRE Corporation, a nonprofit organization that manages seven federally funded research and development centers. He oversees MITRE’s internal research and development program and corporate technology transfer efforts, which are designed to meet the needs of MITRE’s federal sponsors. Previously, Dr. Schnitzer was the Director of Biomedical Sciences at MITRE, managing the organization’s health transformation research and development program.

Before joining MITRE, Dr. Schnitzer was the Director of the Defense Sciences Office at the Defense Advanced Research Projects Agency (DARPA). In this role, he led a team of 20 program

managers and 70 support staff overseeing research and development across multiple domains, from life sciences and biomedical research to quantum physics. Before DARPA, Dr. Schnitzer was at Boston Scientific Corporation as Chief Medical Officer and Senior Vice President.

He received a BS in chemical engineering from Worcester Polytechnic Institute, a PhD in chemical engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. Dr. Schnitzer completed his residency training program in general surgery at the Brigham and Women’s Hospital, Boston, and a fellowship in pediatric surgery at Children’s Hospital, Boston.

Norman E. Sharpless, MD Director National Cancer Institute (NCI)

Dr. Ned Sharpless was officially sworn in as the 15th director of the National Cancer Institute (NCI) on Oct. 17, 2017. Prior to his appointment, Dr. Sharpless served as the director of the University of North Carolina Lineberger Comprehensive Cancer Center, a position he held since January 2014.

Dr. Sharpless was a Morehead Scholar at UNC–Chapel Hill and received his undergraduate degree in mathematics. He went on to pursue his medical degree from the UNC School of Medicine, graduating with honors and distinction in 1993. He then completed his internal medicine residency at the Massachusetts General Hospital and a hematology/oncology

fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston.

After 2 years on the faculty at Harvard Medical School, he joined the faculty of the UNC School of Medicine in the Departments of Medicine and Genetics in 2002. He became the Wellcome Professor of Cancer Research at UNC in 2012.

Dr. Sharpless is a member of the Association of American Physicians, as well as the American Society for Clinical Investigation (ASCI), the nation’s oldest honor society for physician–scientists, and served on the ASCI council from 2011 to 2014. Dr. Sharpless was an associate editor of Aging Cell and deputy editor of the Journal of Clinical Investigation. He has authored more than 150 original scientific papers, reviews, and book chapters, and is an inventor on 10 patents. He cofounded two clinical-stage biotechnology companies: G1 Therapeutics and HealthSpan Diagnostics.

In addition to serving as Director of NCI, Dr. Sharpless continues his research in understanding the biology of the aging process that promotes the conversion of normal self-renewing cells into dysfunctional cancer cells. Dr. Sharpless has made seminal contributions to the understanding of the relationship between aging and cancer, and in the preclinical development of novel therapeutics for melanoma, lung cancer and breast cancer.

22 23

Ann SkyeAssociate Director for Employee Health Management QuintilesIMS

Ms. Ann Skye is responsible for the strategy, design and implementation of her company’s comprehensive and robust well-being program and initiatives across the globe, serving over 36,000 employees. Her current focus is on post-merger integrations, including global tobacco-free workplace, employee assistance program and resilience/energy management initiatives to assist others through continual change. Ms. Skye serves on the boards of local Girls on the Run and YMCA organizations and strives to have a positive impact whether close to home or oceans away.

Ms. Skye received her MPH from The University of North Carolina and her BSN from The University of Michigan. She has been involved in the CEO Cancer Gold Standard program from the beginning as a successful company applicant in the first wave of accreditations in 2006, an attendee at the 2007 CEO Roundtable on Cancer meeting in NYC, and on the task force and accreditation review board since that time. She is excited to lead the Global CEO Gold Standard subcommittee as it assists companies in extending their Gold Standard impact worldwide.

Gail StephensVice President, Research and Development SAS

Bruno StriginiChief Executive Officer Novartis Oncology

Mr. Bruno Strigini has been CEO of Novartis Oncology since July 1, 2016. He is a member of the Executive Committee of Novartis.

Mr. Strigini joined Novartis in June 2014 as President of Oncology. Prior to Novartis, he was President of MSD for Europe and Canada (Merck & Co. Inc. in the United States and Canada). He previously worked at Schering-Plough, UCB Celltech and SmithKline Beecham, and his roles included President of International Operations, President of Japan and Asia-Pacific, Head of Global Marketing and Business Development, and Managing Director positions.

Mr. Strigini holds a master of business administration from IMD in Switzerland, a doctorate in pharmacy from the University of Montpellier in France, and a master’s in microbiology from Heriot-Watt University in the United Kingdom. He is an elected member of the French National Academy of Pharmacy, and in 2014 was awarded a Doctor Honoris Causa from Universidad Internacional Menendez Pelayo in Spain.

24

Zhen Su, MDVice President and Head of Global Medical Affairs – Oncology EMD Serono

Dr. Zhen Su leads medical strategy and the team for EMD Serono. A physician executive with more than 15 years of experience, Dr. Su has strong clinical expertise in oncology, immuno-oncology and urology.

He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, Dr. Su served as Associate Vice President and Global Head of Jevtana® (cabazitaxel) at Sanofi. Dr. Su previously held several academic positions, including Assistant Professor of Surgery at Duke University, where he also received his postdoc fellowship in immuno-oncology.

Dr. Su has deep ties to the oncology community, having worked with leading oncologists at organizations globally. He earned his MD degree from the Technical University of Dresden, Germany, and completed his MBA training at the University of Toronto, Canada.

Craig L. Tendler, MDVice President, Oncology Clinical Development and Global Medical Affairs Janssen

Dr. Craig Tendler is responsible for creating robust development plans and data generation activities for all products in the Janssen Oncology portfolio, from late development through registration and lifecycle management, that support regulatory approval and provide access for the benefit of patients. He works closely with early development and the disease area strongholds to implement a seamless end-to-end oncology clinical research strategy that incorporates compelling science and addresses areas of high unmet medical need.

Dr. Tendler has overseen and coordinated 26 major drug approvals by national regulatory agencies, including 12 by the US Food and Drug Administration (FDA). Most recently his team

worked in collaboration with FDA and EMA to secure the expeditious worldwide approval of IMBRUVICA for relapsed mantle cell lymphoma, Waldenstrom’s Macroglobulinemia and CLL as well as ZYTIGA® for the treatment of metastatic castration resistant prostate cancer and DARZALEX for refractory multiple myeloma.

Dr. Tendler and his team have played a key role in achieving several FDA Breakthrough Designations for ibrutinib and daratumumab, in collaboration with co-development partners Pharmacyclics and Genmab, respectively.

In addition to his pharmaceutical industry experience, Dr. Tendler has served as Assistant Professor of Pediatrics at the Mount Sinai School of Medicine in New York City and was a research fellow and recipient of a Physician Scientist Training Award at the National Cancer Institute.

Dr. Tendler earned his undergraduate degree from Cornell University and graduated from the Mount Sinai School of Medicine with high honors (AOA). He is board certified in Pediatrics with a subspecialty in Hematology-Oncology.

24 25

Christopher A. ViehbacherImmediate Past Chairman, CEO Roundtable on Cancer Managing Partner, Gurnet Point Capital

Mr. Christopher Viehbacher is the Managing Partner of Gurnet Point Capital, a Boston-based investment fund associated with the Bertarelli family with a $2 billion capital allocation. He is also a member of the Board of Pure Tech Health plc; the Chairman of Vedanta, a Pure Tech portfolio company; and a member of the Board of Trustees of Northeastern University.

Mr. Viehbacher is the former CEO and member of the board of directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston.

Prior to joining Sanofi, Mr. Viehbacher spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the US as President of GSK North America. He was a member of the board of directors of GSK plc in London and Co-President of GSK’s Portfolio Management Board. He began his career with Price Waterhouse after graduating with a degree in Commerce at Queen’s University in Canada.

Mr. Viehbacher has been a strong advocate for the health care industry. Current and past advocacy roles include:

Former Co-chair with Bill Gates for the CEO Roundtable on Neglected Diseases, Immediate Past Chairman of the CEO Roundtable on Cancer, Chairman of the Board of the Pharmaceutical Research and Manufacturers of America in Washington, and President of the European Federation of Pharmaceutical Industries and Associations in Brussels. He is Chair of the Health Governors at World Economic Forum and Co-chair of a WEF initiative to create a Global Charter for Healthy Living and Member of the International Business Council.

Mr. Viehbacher has in the past served on various advisory groups at MIT, Duke University and Queen’s University at Kingston, Ontario. He has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide, and France’s highest civilian honor, the Legion d’Honneur.

Karen J. WaltersCo-Chair, CEO Cancer Gold Standard Task Force Clinical Service Support Director, Independence Blue Cross

Ms. Karen Walters supports special projects and key strategic initiatives for the Chief Medical Officer at Independence Blue Cross, the leading health insurance organization in southeastern Pennsylvania. With its affiliates, the company serves nearly nine million people in 32 states and Washington, DC. Prior to this position, she served as the Director of Associate Wellness and Communications where she developed the annual wellness operating plan for the company’s more than 4,400 associates and oversaw all internal and external wellness communications.

Before her tenure in the health insurance industry, Ms. Walters held a variety of roles in the financial services and investment management industry. She has extensive experience in

strategic marketing and communications, and start-up departmental ventures.

Ms. Walters has a master’s degree in finance from New York University, a bachelor’s degree from Villanova University in business administration with a marketing concentration, and an associate’s degree from the Parson’s School of Design. She is currently enrolled in Rowan University’s Master’s in Wellness and Lifestyle Management Program.

26

Névine ZariffaVice President and Head, Biometrics and Information Sciences AstraZeneca

Ms. Névine Zariffa was born in Cairo, Egypt, and was raised in Montréal, Canada. After her training at McGill University and at the University of Waterloo (mathematics and statistics), she began her career as a statistician supporting agricultural research before moving to Philadelphia to join SmithKline Beecham in 1991, which went on to become GlaxoSmithKline. She joined AstraZeneca in November 2011 and is currently VP and Head of Biometrics and Information Sciences in Global Medicine Development.

Over the last 25 years, Ms. Zariffa has amassed a wealth of experience in her specialist area and also in driving strategic programs. She has supported early and late-stage clinical development

and marketed products – primarily in the area of cardiovascular and metabolism – and has led global teams of quantitative experts across many quantitative disciplines. Ms. Zariffa has also led, or played an integral part, in numerous strategic initiatives, working with company colleagues, medical associations, academics and other groups (both PhRMA and FDA-sponsored) to enhance the value of quantitative sciences beyond the traditional role of designing, analyzing and interpreting clinical trials. Ms. Zariffa has been a statistical reviewer for The Lancet and is the author or co-author of over 25 publications in peer reviewed biostatistics and medical journals.

CEO Roundtable on Cancer Staff

John N. Dornan, Jr.Executive Director CEO Roundtable on Cancer

Mr. John N. Dornan, Jr. is the Executive Director of the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs dedicated to eliminating cancer as a public health threat. Mr. Dornan provides administrative oversight to the group’s initiatives, including the CEO Cancer Gold Standard™ workplace accreditation program, which recognizes employers who provide state-of-the-art preventive care, wellness support and cancer treatment, and the Life Sciences Consortium, which encourages researchers to work collaboratively to accelerate the discovery and development of new therapies for cancer patients. Mr. Dornan also serves as Chief Operating Officer of Project Data Sphere, LLC, an independent initiative of the Life Sciences Consortium.

The Project Data Sphere platform provides one place where the research community can broadly share, integrate and analyze patient-level, comparator-arm data from academic and industry phase III cancer clinical trials.

Mr. Dornan formerly headed corporate public relations for SAS, the world’s largest privately held software company, and served as Vice President of Trone, a mid-Atlantic regional advertising and public relations agency, where he specialized in communications related to corporate mergers and acquisitions. He also held marketing and communications positions with Healthsource North Carolina prior to its acquisition by Cigna. He began his career in North Carolina’s Department of Health and Human Services, where he provided outreach and communications services for the state’s welfare reform efforts and programs for children and families, including the nationally renowned Smart Start early childhood initiative created by Gov. James B. Hunt Jr.

26 27

Lynda Goldberg, MSPH, MBAUniversity Outreach Coordinator CEO Cancer Gold Standard™

Ms. Lynda Goldberg is the CEO Cancer Gold Standard™ University Outreach Coordinator working to assist universities in their efforts to achieve Gold Standard accreditation.

Ms. Goldberg has worked throughout her career to promote access to high-quality cancer care, focusing on educating patients about wise choices. She is a former registered respiratory therapist, which provided a clinical background to justify promoting a restaurant smoking ban in Rochester, MN, in 2002. She has since shepherded the University of North Carolina Hospitals, The Ohio State University Wexner Medical Center, and The Ohio State University campus to CEO Cancer Gold Standard accreditation.

Ms. Goldberg is a National Committee for Quality Assurance certified content expert for patient-centered medical homes and patient-centered specialty practices, which sets standards for recognition of patient care providers achieving specific quality metrics.

Megan R. Granda, PhDProject Manager Project Data Sphere, LLC

Dr. Megan Granda, PhD, is Project Manager for Project Data Sphere (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium. The initiative provides a free digital library-laboratory that gives the research community one place to broadly share, integrate and analyze historical, patient-level data from academic and industry phase III cancer clinical trials. Ms. Granda works closely with Dave Handelsman to steward industry and academic partners of the Project Data Sphere platform, manage special projects (such as the biannual FDA-PDS symposium), and oversee daily operations.

Over the past 10 years, Dr. Granda worked closely with research faculty to provide administrative direction to centers and institutions at Duke University and the University of North Carolina, Chapel Hill. She is certified to train biomedical investigators in team science through the National Research Mentoring Network, and is a graduate of the Center for Creative Leadership’s renowned Leadership Development Program. Dr. Granda has worked extensively with academic faculty of all ranks in the schools of arts and sciences, law, public policy, business, medicine and nursing to enable and enhance their institutional leadership, professional development and scholarly output.

28

David HandelsmanVice President, Development Project Data Sphere, LLC

Mr. David Handelsman is the Vice President of Development at Project Data Sphere, LLC, an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium. The initiative provides a free digital library-laboratory that gives the research community one place to broadly share, integrate and analyze historical, patient-level data from academic and industry phase III cancer clinical trials. In this role, Mr. Handelsman is responsible for the strategic growth of the Project Data Sphere platform in terms of patient lives, researcher value and technological capabilities.

Mr. Handelsman was formerly responsible for strategic growth and product development at d-Wise, a high tech company focused on developing software and delivering services to the health care industries. He played a key role in leading the development and marketing of d-Wise’s patient data anonymization software application.

Prior to joining d-Wise, Mr. Handelsman held a variety of leadership roles at SAS where he served as the leading expert in clinical research and related health care fields, and was instrumental in the success of the organization’s clinical trial data sharing initiative. Mr. Handelsman also led data management, programming and biostatistics teams within the CRO industry, and recently completed his term as the Chair of the CDISC Advisory Council.

Nicole HayesExecutive Associate CEO Roundtable on Cancer

Ms. Nicole Hayes is the Executive Associate for the CEO Roundtable on Cancer, a nonprofit organization comprising CEOs who are dedicated to eliminating cancer as a public health threat. Her responsibilities include human resource and accounting support, not only for the CEO Roundtable on Cancer, but also for the CEO Roundtable on Cancer-China, an independent, nonprofit subsidiary headquartered in Shanghai, China. Ms. Hayes is also responsible for maintaining database information, assisting with communication efforts and providing support to the staff and members of the CEO Roundtable on Cancer.

Prior to joining the CEO Roundtable in 2016, Ms. Hayes worked 13 years for Robert A. Ingram, the Past Chairman and Co-Founder of the CEO Roundtable on Cancer and General Partner at Hatteras Venture Partners. She began her career in the human resource and recruiting fields at GlaxoSmithKline. Ms. Hayes is a graduate of East Carolina University.

28 29

Becky KeithExecutive Coordinator CEO Roundtable on Cancer

Ms. Becky Keith is the Executive Coordinator supporting Dr. Martin J. Murphy in his role as Chief Executive Officer of the CEO Roundtable on Cancer. In addition to administrative support, Ms. Keith’s responsibilities include coordination of global travel arrangements, meeting planning, event scheduling and interacting with CEOs, government officials and international contacts. She maintains the HR records for the CEO Roundtable on Cancer and for the CEO Roundtable on Cancer-China. Ms. Keith also assists with communications and provides support to the staff and members of the CEO Roundtable on Cancer as needed.

Prior to beginning her employment with Dr. Murphy in August 2009, Ms. Keith worked with GlaxoSmithKline for 23 years in various departments throughout the RTP campus. Her last assignment was in the Robert A. Ingram Sales Training Center, where she supported the training efforts of the newly hired sales representatives.

Therese MartinProgram Manager CEO Cancer Gold Standard™

Ms. Therese Martin serves as the Program Manager for the CEO Cancer Gold Standard™, a workplace accreditation program that encourages and recognizes the commitment of organizations that take concrete actions to address cancer in their workplaces. The Gold Standard is an initiative of the CEO Roundtable on Cancer, a nonprofit organization comprised of CEOs dedicated to eliminating cancer as a public health threat. Responsibilities include providing assistance to employers interested in adopting Gold Standard, conducting initial reviews of Gold Standard accreditation applications, serving as the primary interface with Gold Standard Task Force Members, and conducting outreach efforts to educate employers and promote the Gold Standard. Ms. Martin also manages program data and provides general

support to CEO Roundtable on Cancer initiatives.

Prior to joining the CEO Roundtable in 2011, Ms. Martin worked as a program manager in a wide range of industries, including the military, software development, retail and nonprofit sectors. She is a graduate of the United States Air Force Academy, and earned her MBA in contracts and acquisition from Western New England College.